207 related articles for article (PubMed ID: 16210393)
1. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
Quik M; McIntosh JM
J Pharmacol Exp Ther; 2006 Feb; 316(2):481-9. PubMed ID: 16210393
[TBL] [Abstract][Full Text] [Related]
2. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
3. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
Quik M; Sum JD; Whiteaker P; McCallum SE; Marks MJ; Musachio J; McIntosh JM; Collins AC; Grady SR
Mol Pharmacol; 2003 May; 63(5):1169-79. PubMed ID: 12695545
[TBL] [Abstract][Full Text] [Related]
4. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Quik M; Campos C; Grady SR
Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
[TBL] [Abstract][Full Text] [Related]
5. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Lai A; Sum J; Fan H; McIntosh JM; Quik M
Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic receptors as CNS targets for Parkinson's disease.
Quik M; Bordia T; O'Leary K
Biochem Pharmacol; 2007 Oct; 74(8):1224-34. PubMed ID: 17631864
[TBL] [Abstract][Full Text] [Related]
7. Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.
Quik M; Perez XA; Grady SR
Biochem Pharmacol; 2011 Oct; 82(8):873-82. PubMed ID: 21684266
[TBL] [Abstract][Full Text] [Related]
8. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
Bordia T; Grady SR; McIntosh JM; Quik M
Mol Pharmacol; 2007 Jul; 72(1):52-61. PubMed ID: 17409284
[TBL] [Abstract][Full Text] [Related]
9. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Quik M; Polonskaya Y; Kulak JM; McIntosh JM
J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
[TBL] [Abstract][Full Text] [Related]
10. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.
Kulak JM; McIntosh JM; Quik M
Mol Pharmacol; 2002 Jan; 61(1):230-8. PubMed ID: 11752225
[TBL] [Abstract][Full Text] [Related]
11. Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.
Yang KC; Jin GZ; Wu J
Acta Pharmacol Sin; 2009 Jun; 30(6):740-51. PubMed ID: 19498417
[TBL] [Abstract][Full Text] [Related]
12. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
13. Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.
Quik M; Bordia T; Forno L; McIntosh JM
J Neurochem; 2004 Feb; 88(3):668-79. PubMed ID: 14720216
[TBL] [Abstract][Full Text] [Related]
14. α6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity.
Berry JN; Engle SE; McIntosh JM; Drenan RM
Neuroscience; 2015 Sep; 304():161-75. PubMed ID: 26210579
[TBL] [Abstract][Full Text] [Related]
15. Multiple roles for nicotine in Parkinson's disease.
Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
[TBL] [Abstract][Full Text] [Related]
16. Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.
Drenan RM; Grady SR; Steele AD; McKinney S; Patzlaff NE; McIntosh JM; Marks MJ; Miwa JM; Lester HA
J Neurosci; 2010 Jul; 30(29):9877-89. PubMed ID: 20660270
[TBL] [Abstract][Full Text] [Related]
17. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus.
Bohr IJ; Ray MA; McIntosh JM; Chalon S; Guilloteau D; McKeith IG; Perry RH; Clementi F; Perry EK; Court JA; Piggott MA
Exp Neurol; 2005 Feb; 191(2):292-300. PubMed ID: 15649484
[TBL] [Abstract][Full Text] [Related]
18. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
19. Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain.
Perry DC; Mao D; Gold AB; McIntosh JM; Pezzullo JC; Kellar KJ
J Pharmacol Exp Ther; 2007 Jul; 322(1):306-15. PubMed ID: 17446303
[TBL] [Abstract][Full Text] [Related]
20. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice.
Champtiaux N; Han ZY; Bessis A; Rossi FM; Zoli M; Marubio L; McIntosh JM; Changeux JP
J Neurosci; 2002 Feb; 22(4):1208-17. PubMed ID: 11850448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
